Trouble viewing? Click here.

Catalent to Speak at BIO Digital

Join our experts as they share insights on:

  • R&D Leadership During the Pandemic: John Chiminski, Chair & CEO
  • Technology Integrators in Cell & Gene Therapy: Julien Meissonnier, VP & CSO
  • A Novel Approach for High-Expressing CHO Cell Line Engineering: Greg Bleck, Ph.D., Global Head of R&D, Biologics

The First and Largest CRO in Japan Offering Services Globally

  • Largest CRO in Japan with 1,200+ CRAs
  • Involved in more than 80% of new drug development in Japan
  • Connected with 2,600+ clinical sites in Asia-Pacific
  • Among top 3 largest CDMOs in Japan

Schedule a Virtual Meeting with Us at BIO!

Enabling Commercial Manufacturing for Complex Small Molecule Drugs

With COVID-19, the pressure to reduce development times is high. Learn how we are leveraging our process science expertise and engineering experience to enable rapid scale-up while reducing manufacturing CoGs. Read about our approach here and meet with our team at BIO Digital: cdmo@biovectra.com

How Can Extrusion Benefit your Pharmaceutical Oral Drug Product?

As a continuous manufacturing process, extrusion was cemented in pharmaceutical manufacturing in 1980s with market launch of sustained-release Verapamil, which contains embedded crystalline active pharmaceutical ingredient (API) in polymers. Following the Verapamil launch, researchers have turned to hot melt extrusion (HME) as an effective enabling technology to manufacture amorphous solid dispersions (ASDs) for poorly soluble compounds.


Click here to learn more.

Transforming Clinical Development and Discovery with Multi-omic Data in the Era of Precision Medicine

Join industry experts as they propose best practices for incorporating translational omic data in clinical development in order to yield novel insights and improve patient / study outcomes. Register now.

Transforming medicine with expertise, flexibility and scale

Join usfor a live webcast that will announce our progress on the 2020 investments to our Pharma Services business and provide focused insight on Thermo Fisher Scientific's expanding gene therapy capabilities. We will also cover an update on our strategy to ensure the delivery of drugs to customers and patients in lieu of the COVID-19 outbreak, as well as our evolving direct response to the virus through several ongoing projects. Register Now.